The induction and maintenance of unconsciousness with no feeling of pain is accomplished by the use of general anaesthesia drugs. Basically, it is an unconscious state that is generated along with a partial or whole absence of defensive reflexes. It is inhaled or delivered intravenously in conjunction with medication. Sevoflurane and desflurane are inhalation anaesthetics, whereas propofol, etiomide, and ketamine are some intravenous general anaesthetic medications. A variety of surgical procedures involving the heart, hip and knee replacements, cancer, and the gastrointestinal tract all need general anaesthesia.
US General Anesthesia Drugs Market Driving Factors and Challenges
Over the past few decades, the US has seen a considerable increase in the prevalence of cancer. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, skin melanoma, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukaemia, pancreatic cancer, thyroid cancer, and liver cancer. The list is arranged in descending order based on estimated new cases in 2020. As more people develop cancer, more procedures will be performed since, in many cases, surgery is the only way to cure a tumor—especially if the cancer is localised. Since general anaesthesia is frequently used for surgical procedures, the rising incidence of cancer will therefore propel the expansion of the general anaesthesia market in the United States.
However, general anaesthetic and sedative drug use in young children and pregnant women was the subject of warnings from the US FDA in April 2017. The FDA raised concerns about the possible dangers associated with repeated or prolonged use of these medications, especially in children under three years old and pregnant women, even though they are necessary for surgical and stressful treatments in these populations. A possible barrier to the market's expansion could be the healthcare community's reduced adoption of general anaesthesia medications as a result of this caution. The FDA's cautions should be carefully considered while weighing the advantages and disadvantages of these medications, as they may have an impact on which patient populations use them.
Impact of COVID-19 on US General Anesthesia Drugs Market
With healthcare systems under stress and demand declining as a result of elective surgery postponed or cancelled, the COVID-19 pandemic is predicted to have a negative effect on the general anaesthesia drug market. Article published in February 2023 in a review for Medical and Pharmacological Sciences noted that individuals with recent or ongoing COVID-19 infections are more likely to experience post-operative problems and death. Anaesthesia use becomes much more complicated when considering the impossibility of a safe interval between COVID-19 therapy and surgery, in addition to possible medication interactions. Yet, as delayed elective surgeries begin again, the use of anaesthetic medications rises as life progressively gets back to normal.
US General Anesthesia Drugs Market Key Players:
The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Abbott Laboratories, AbbVie, Akorn, AstraZeneca plc, Baxter International Inc., Gilead Sciences, Inc, Heritage Pharmaceuticals Inc., Novartis AG, Par Pharmaceutical, Pfizer Inc., Others.
US General Anesthesia Drugs Market Segmentation:
By Route of Administration: Based on the Route of Administration, US General Anesthesia Drugs Market is segmented as; Inhalational (Desflurane, Isoflurane, Nitrous Oxide, Sevoflurane), Intravenous (Benzodiazepines, Etomidate, Fentanyl, Ketamine, Methohexital Sodium, Propofol, Remifentanil, Others).
By End User: Based on the End User, US General Anesthesia Drugs Market is segmented as; Ambulatory Surgery Centres, Hospitals.
By Region: This research also includes data for Central Region, North Region, South Region.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.